{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:56:59Z","timestamp":1790639819699,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Tri-Service General Hospital Research Foundation","award":["TSGH-B-114022"],"award-info":[{"award-number":["TSGH-B-114022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11096-025-02026-7","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T08:13:30Z","timestamp":1761034410000},"page":"2037-2050","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative risks of inflammatory bowel disease in patients with type 2 diabetes mellitus treated with SGLT-2 inhibitors versus DPP-4 inhibitors: a real-world nationwide cohort study"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6618-2454","authenticated-orcid":false,"given":"Ya-Ju","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3286-0780","authenticated-orcid":false,"given":"Wu-Chien","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"12","key":"2026_CR1","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","volume":"12","author":"GG Kaplan","year":"2015","unstructured":"Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720\u20137. https:\/\/doi.org\/10.1038\/nrgastro.2015.150.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"2026_CR2","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1007\/s10620-024-08518-2","volume":"69","author":"CJ Kuo","year":"2024","unstructured":"Kuo CJ, Lin CY, Le PH, et al. Temporal trends of inflammatory bowel diseases in Taiwan from 2016 to 2020: a population-based study. Dig Dis Sci. 2024;69(9):3172\u20139. https:\/\/doi.org\/10.1007\/s10620-024-08518-2.","journal-title":"Dig Dis Sci"},{"issue":"4","key":"2026_CR3","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.cgh.2019.07.052","volume":"18","author":"T Jess","year":"2020","unstructured":"Jess T, Jensen BW, Andersson M, et al. Inflammatory bowel diseases increase risk of type 2 diabetes in a nationwide cohort study. Clin Gastroenterol Hepatol. 2020;18(4):881-8.e1. https:\/\/doi.org\/10.1016\/j.cgh.2019.07.052.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2026_CR4","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.cgh.2019.09.016","volume":"18","author":"S-W Lai","year":"2020","unstructured":"Lai S-W, Kuo Y-H, Liao K-F. Association between inflammatory bowel disease and diabetes mellitus. Clin Gastroenterol Hepatol. 2020;18(4):1002\u20133. https:\/\/doi.org\/10.1016\/j.cgh.2019.09.016.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"2026_CR5","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s00535-023-01983-y","volume":"58","author":"S Shinzaki","year":"2023","unstructured":"Shinzaki S, Sato T, Fukui H. Antidiabetic drugs for IBD: a long but promising road ahead for drug repositioning to target intestinal inflammation. J Gastroenterol. 2023;58(6):598\u20139. https:\/\/doi.org\/10.1007\/s00535-023-01983-y.","journal-title":"J Gastroenterol"},{"issue":"11","key":"2026_CR6","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.2337\/dc19-0162","volume":"42","author":"T Wang","year":"2019","unstructured":"Wang T, Yang JY, Buse JB, et al. Dipeptidyl peptidase 4 inhibitors and risk of inflammatory bowel disease: real-world evidence in U.S. adults. Diabetes Care. 2019;42(11):2065\u201374. https:\/\/doi.org\/10.2337\/dc19-0162.","journal-title":"Diabetes Care"},{"issue":"1","key":"2026_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/ecco-jcc\/jjaa136","volume":"15","author":"CH Tseng","year":"2021","unstructured":"Tseng CH. Metformin use is associated with a lower risk of inflammatory bowel disease in patients with type 2 diabetes mellitus. J Crohns Colitis. 2021;15(1):64\u201373. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa136.","journal-title":"J Crohns Colitis"},{"key":"2026_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ph15121538","author":"CH Tseng","year":"2022","unstructured":"Tseng CH. Pioglitazone has a null association with inflammatory bowel disease in patients with type 2 diabetes mellitus. Pharmaceuticals (Basel). 2022;15(12):1538. https:\/\/doi.org\/10.3390\/ph15121538.","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026_CR9","doi-asserted-by":"publisher","first-page":"100979","DOI":"10.1016\/j.eclinm.2021.100979","volume":"37","author":"M Villumsen","year":"2021","unstructured":"Villumsen M, Schelde AB, Jimenez-Solem E, et al. GLP-1 based therapies and disease course of inflammatory bowel disease. EClin Med. 2021;37:100979. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100979.","journal-title":"EClin Med"},{"key":"2026_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-71599-2","author":"R Hasan","year":"2020","unstructured":"Hasan R, Lasker S, Hasan A, et al. Canagliflozin ameliorates renal oxidative stress and inflammation by stimulating AMPK\u2013Akt\u2013eNOS pathway in the isoprenaline-induced oxidative stress model. Sci Rep. 2020;10(1):14659. https:\/\/doi.org\/10.1038\/s41598-020-71599-2.","journal-title":"Sci Rep"},{"key":"2026_CR11","doi-asserted-by":"publisher","first-page":"109368","DOI":"10.1016\/j.cbi.2021.109368","volume":"335","author":"HH Arab","year":"2021","unstructured":"Arab HH, Al-Shorbagy MY, Saad MA. Activation of autophagy and suppression of apoptosis by dapagliflozin attenuates experimental inflammatory bowel disease in rats: targeting AMPK\/mTOR, HMGB1\/RAGE and Nrf2\/HO-1 pathways. Chem Biol Interact. 2021;335:109368. https:\/\/doi.org\/10.1016\/j.cbi.2021.109368.","journal-title":"Chem Biol Interact"},{"key":"2026_CR12","doi-asserted-by":"publisher","first-page":"176166","DOI":"10.1016\/j.ejphar.2023.176166","volume":"960","author":"HS Althagafy","year":"2023","unstructured":"Althagafy HS, Ali FEM, Hassanein EHM, et al. Canagliflozin ameliorates ulcerative colitis via regulation of TLR4\/MAPK\/NF-kappaB and Nrf2\/PPAR-gamma\/SIRT1 signaling pathways. Eur J Pharmacol. 2023;960:176166. https:\/\/doi.org\/10.1016\/j.ejphar.2023.176166.","journal-title":"Eur J Pharmacol"},{"issue":"10\u201311","key":"2026_CR13","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s00011-023-01796-y","volume":"72","author":"YJ Kim","year":"2023","unstructured":"Kim YJ, Jin J, Kim DH, et al. SGLT2 inhibitors prevent LPS-induced M1 macrophage polarization and alleviate inflammatory bowel disease by downregulating NHE1 expression. Inflamm Res. 2023;72(10\u201311):1981\u201397. https:\/\/doi.org\/10.1007\/s00011-023-01796-y.","journal-title":"Inflamm Res"},{"issue":"1","key":"2026_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10787-023-01227-8","volume":"32","author":"A Makaro","year":"2024","unstructured":"Makaro A, Swierczynski M, Pokora K, et al. Empagliflozin attenuates intestinal inflammation through suppression of nitric oxide synthesis and myeloperoxidase activity in in vitro and in vivo models of colitis. Inflammopharmacology. 2024;32(1):377\u201392. https:\/\/doi.org\/10.1007\/s10787-023-01227-8.","journal-title":"Inflammopharmacology"},{"issue":"1","key":"2026_CR15","doi-asserted-by":"publisher","first-page":"8630","DOI":"10.1038\/s41598-024-59320-z","volume":"14","author":"Z Li","year":"2024","unstructured":"Li Z, Zhang X, Chen H, et al. Empagliflozin in children with glycogen storage disease-associated inflammatory bowel disease: a prospective, single-arm, open-label clinical trial. Sci Rep. 2024;14(1):8630. https:\/\/doi.org\/10.1038\/s41598-024-59320-z.","journal-title":"Sci Rep"},{"key":"2026_CR16","doi-asserted-by":"publisher","first-page":"1365700","DOI":"10.3389\/fendo.2024.1365700","volume":"15","author":"A Klinc","year":"2024","unstructured":"Klinc A, Groselj U, Mlinaric M, et al. Case report: the success of empagliflozin therapy for glycogen storage disease type 1b. Front Endocrinol (Lausanne). 2024;15:1365700. https:\/\/doi.org\/10.3389\/fendo.2024.1365700.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-025-00795-5","author":"MD Milosevic","year":"2025","unstructured":"Milosevic MD, Skakic A, Kecman B, et al. Clinical and genetic profile of 35 patients with glycogen storage disease type 1b: a comparative analysis before and during SGLT2 inhibitor therapy. Mol Diagn Ther. 2025. https:\/\/doi.org\/10.1007\/s40291-025-00795-5.","journal-title":"Mol Diagn Ther"},{"key":"2026_CR18","doi-asserted-by":"publisher","first-page":"112109","DOI":"10.1016\/j.diabres.2025.112109","volume":"222","author":"CH Hung","year":"2025","unstructured":"Hung CH, Wu JY, Weng YS, et al. Impact of sodium-glucose cotransporter-2 inhibitors on ovarian cancer risk in patients with type 2 diabetes mellitus: a multi-institutional TriNetX study. Diabetes Res Clin Pract. 2025;222:112109. https:\/\/doi.org\/10.1016\/j.diabres.2025.112109.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"2026_CR19","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1007\/s11096-020-01037-w","volume":"42","author":"W Lu","year":"2020","unstructured":"Lu W, Sun S, Wei J, et al. Dipeptidyl peptidase-4 inhibitors and risk of venous thromboembolism: data mining of FDA adverse event reporting system. Int J Clin Pharm. 2020;42(5):1364\u20138. https:\/\/doi.org\/10.1007\/s11096-020-01037-w.","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"2026_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2337\/dc24-1652","volume":"48","author":"A Shin","year":"2025","unstructured":"Shin A, Shin JY, Kang EH. Risk of nephrolithiasis associated with SGLT2 inhibitors versus DPP4 inhibitors among patients with type 2 diabetes: a target trial emulation study. Diabetes Care. 2025;48(2):193\u2013201. https:\/\/doi.org\/10.2337\/dc24-1652.","journal-title":"Diabetes Care"},{"key":"2026_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/clep.S196293","volume":"11","author":"CY Hsieh","year":"2019","unstructured":"Hsieh CY, Su CC, Shao SC, et al. Taiwan\u2019s National Health Insurance Research Database: past and future. Clin Epidemiol. 2019;11:349\u201358. https:\/\/doi.org\/10.2147\/clep.S196293.","journal-title":"Clin Epidemiol"},{"issue":"1","key":"2026_CR22","doi-asserted-by":"publisher","first-page":"6625","DOI":"10.1038\/s41598-023-33674-2","volume":"13","author":"HC Lin","year":"2023","unstructured":"Lin HC, Chung CH, Chen LC, et al. Pioglitazone use increases risk of Alzheimer\u2019s disease in patients with type 2 diabetes receiving insulin. Sci Rep. 2023;13(1):6625. https:\/\/doi.org\/10.1038\/s41598-023-33674-2.","journal-title":"Sci Rep"},{"issue":"11","key":"2026_CR23","doi-asserted-by":"publisher","first-page":"e2135353","DOI":"10.1001\/jamanetworkopen.2021.35353","volume":"4","author":"MC Chung","year":"2021","unstructured":"Chung MC, Hung PH, Hsiao PJ, et al. Association of sodium-glucose transport protein 2 inhibitor use for type 2 diabetes and incidence of gout in Taiwan. JAMA Netw Open. 2021;4(11):e2135353. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.35353.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2026_CR24","doi-asserted-by":"publisher","first-page":"10147","DOI":"10.1038\/s41598-022-13760-7","volume":"12","author":"MC Chung","year":"2022","unstructured":"Chung MC, Hsu HT, Chang CH, et al. Association of SGLT2 inhibitors with lower incidence of death in type 2 diabetes mellitus and causes of death analysis. Sci Rep. 2022;12(1):10147. https:\/\/doi.org\/10.1038\/s41598-022-13760-7.","journal-title":"Sci Rep"},{"issue":"6","key":"2026_CR25","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/cpt.3626","volume":"117","author":"MC Chung","year":"2025","unstructured":"Chung MC, Lin CY, Chang CH, et al. Use of sodium-glucose transport protein 2 inhibitors and the incidence of urolithiasis: a multi-database and cross-country study in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2025;117(6):1775\u201383. https:\/\/doi.org\/10.1002\/cpt.3626.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2026_CR26","doi-asserted-by":"publisher","first-page":"5872","DOI":"10.1038\/s41598-024-81973-z","volume":"15","author":"B Huang","year":"2025","unstructured":"Huang B, Yen CL, Wu CY, et al. SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with type 2 DM. Sci Rep. 2025;15(1):5872. https:\/\/doi.org\/10.1038\/s41598-024-81973-z.","journal-title":"Sci Rep"},{"issue":"5","key":"2026_CR27","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.1007\/s00210-024-03660-0","volume":"398","author":"WL Chuang","year":"2025","unstructured":"Chuang WL, Tsai SC, Yang YC, et al. Correlation between the utilization of sodium-glucose cotransporter-2 (SGLT2) inhibitors and the risk of dementia: a nationwide population-based study in Taiwan. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(5):5835\u201343. https:\/\/doi.org\/10.1007\/s00210-024-03660-0.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1 Pt 1","key":"2026_CR28","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jfma.2020.03.001","volume":"120","author":"CW Lee","year":"2021","unstructured":"Lee CW, Wu SH, Chiu WC, et al. The medications and health care utilization of patients newly diagnosed with type 2 diabetes mellitus: a nationwide population-based cohort study. J Formos Med Assoc. 2021;120(1 Pt 1):130\u20136. https:\/\/doi.org\/10.1016\/j.jfma.2020.03.001.","journal-title":"J Formos Med Assoc"},{"issue":"3","key":"2026_CR29","doi-asserted-by":"publisher","first-page":"e3603","DOI":"10.1002\/dmrr.3603","volume":"39","author":"TC Lee","year":"2023","unstructured":"Lee TC, Chen JC, Lin SY, et al. Statin use in patients with type 2 diabetes has lower risk of hip fractures: a Taiwan national population-based study. Diabetes Metab Res Rev. 2023;39(3):e3603. https:\/\/doi.org\/10.1002\/dmrr.3603.","journal-title":"Diabetes Metab Res Rev"},{"key":"2026_CR30","doi-asserted-by":"publisher","first-page":"e079475","DOI":"10.1136\/bmj-2024-079475","volume":"386","author":"A Shin","year":"2024","unstructured":"Shin A, Koo BK, Lee JY, et al. Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40\u201369 years with type 2 diabetes: population based cohort study. BMJ. 2024;386:e079475. https:\/\/doi.org\/10.1136\/bmj-2024-079475.","journal-title":"BMJ"},{"issue":"4","key":"2026_CR31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1167\/iovs.66.4.58","volume":"66","author":"SY Pan","year":"2025","unstructured":"Pan SY, Weng CH, Tsai SF, et al. Use of SGLT2 inhibitors versus DPP-4 inhibitors and age-related macular degeneration in patients withtype 2 diabetes: a multinational cohort study. Investig Ophthalmol Vis Sci. 2025;66(4):58. https:\/\/doi.org\/10.1167\/iovs.66.4.58.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2026_CR32","doi-asserted-by":"publisher","first-page":"112122","DOI":"10.1016\/j.diabres.2025.112122","volume":"223","author":"TC Chang","year":"2025","unstructured":"Chang TC, Liang YC, Lai CC, et al. Comparison of SGLT2 and DPP4 inhibitors on clinical outcomes in COPD patients with diabetes: a nationwide cohort study. Diabetes Res Clin Pract. 2025;223:112122. https:\/\/doi.org\/10.1016\/j.diabres.2025.112122.","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"2026_CR33","doi-asserted-by":"publisher","first-page":"e0314454","DOI":"10.1371\/journal.pone.0314454","volume":"20","author":"Y Cho","year":"2025","unstructured":"Cho Y, Shin SH, Park MA, et al. The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillation. PLoS ONE. 2025;20(2):e0314454. https:\/\/doi.org\/10.1371\/journal.pone.0314454.","journal-title":"PLoS ONE"},{"key":"2026_CR34","unstructured":"Peppercorn MA, Cheifetz AS. Definitions, epidemiology, and risk factors for inflammatory bowel disease. 2024. https:\/\/www.uptodate.com. Accessed on 13 Nov 2024."},{"issue":"10","key":"2026_CR35","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.cgh.2022.11.037","volume":"21","author":"N Narula","year":"2023","unstructured":"Narula N, Wong ECL, Pray C, et al. Associations of antibiotics, hormonal therapies, oral contraceptives, and long-term NSAIDS with inflammatory bowel disease: results from the prospective urban rural epidemiology (PURE) study. Clin Gastroenterol Hepatol. 2023;21(10):2649-59.e16. https:\/\/doi.org\/10.1016\/j.cgh.2022.11.037.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2025-005103","author":"T Horii","year":"2025","unstructured":"Horii T, Kawaguchi M, Ikegami Y, et al. Risk of severe lower extremity arterial disease in elderly Japanese patients with type 2 diabetes: a propensity score-matched model analysis of sodium-glucose cotransporter 2 inhibitors versus metformin. BMJ Open Diabetes Res Care. 2025;13(4):e005103. https:\/\/doi.org\/10.1136\/bmjdrc-2025-005103.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2026_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70057","author":"T Sarabhai","year":"2025","unstructured":"Sarabhai T, Kostev K. SGLT2 inhibitor therapy and lower incidence of iron deficiency anaemia in patients with type 2 diabetes: a retrospective cohort study from Germany. Diabetes Obes Metab. 2025. https:\/\/doi.org\/10.1111\/dom.70057.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2026_CR38","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1111\/dom.15632","volume":"26","author":"M Shikamura","year":"2024","unstructured":"Shikamura M, Takayama A, Takeuchi M, et al. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a retrospective nationwide claims database study in Japan. Diabetes Obes Metab. 2024;26(8):3099\u2013109. https:\/\/doi.org\/10.1111\/dom.15632.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2026_CR39","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s10787-021-00818-7","volume":"29","author":"MA El-Rous","year":"2021","unstructured":"El-Rous MA, Saber S, Raafat EM, et al. Dapagliflozin, an SGLT2 inhibitor, ameliorates acetic acid-induced colitis in rats by targeting NF\u03baB\/AMPK\/NLRP3 axis. Inflammopharmacology. 2021;29(4):1169\u201385. https:\/\/doi.org\/10.1007\/s10787-021-00818-7.","journal-title":"Inflammopharmacology"},{"key":"2026_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26041670","author":"EY Rykova","year":"2025","unstructured":"Rykova EY, Klimontov VV, Shmakova E, et al. Anti-inflammatory effects of SGLT2 inhibitors: focus on macrophages. Int J Mol Sci. 2025;26(4):1670. https:\/\/doi.org\/10.3390\/ijms26041670.","journal-title":"Int J Mol Sci"},{"key":"2026_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012325","author":"R La Grotta","year":"2022","unstructured":"La Grotta R, Frige C, Matacchione G, et al. Repurposing SGLT-2 inhibitors to target aging: available evidence and molecular mechanisms. Int J Mol Sci. 2022;23(20):12325. https:\/\/doi.org\/10.3390\/ijms232012325.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2026_CR42","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s10557-020-07083-w","volume":"35","author":"L Uthman","year":"2021","unstructured":"Uthman L, Kuschma M, Romer G, et al. Novel anti-inflammatory effects of canagliflozin involving hexokinase II in lipopolysaccharide-stimulated human coronary artery endothelial cells. Cardiovasc Drugs Ther. 2021;35(6):1083\u201394. https:\/\/doi.org\/10.1007\/s10557-020-07083-w.","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20176671","author":"E Schonberger","year":"2023","unstructured":"Schonberger E, Mihaljevic V, Steiner K, et al. Immunomodulatory effects of SGLT2 inhibitors-targeting inflammation and oxidative stress in aging. Int J Environ Res Public Health. 2023;20(17):6671. https:\/\/doi.org\/10.3390\/ijerph20176671.","journal-title":"Int J Environ Res Public Health"},{"key":"2026_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/metabo15060411","author":"NM Mindrescu","year":"2025","unstructured":"Mindrescu NM, Guja C, Jinga V, et al. SGLT-2 inhibitors and metabolic outcomes: a primary data study exploring the microbiota-diabetes connection. Metabolites. 2025;15(6):411. https:\/\/doi.org\/10.3390\/metabo15060411.","journal-title":"Metabolites"},{"key":"2026_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cells13191662","author":"V Pellegrini","year":"2024","unstructured":"Pellegrini V, La Grotta R, Carreras F, et al. Inflammatory trajectory of type 2 diabetes: novel opportunities for early and late treatment. Cells. 2024;13(19):1662. https:\/\/doi.org\/10.3390\/cells13191662.","journal-title":"Cells"},{"key":"2026_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/metabo15060397","author":"Y Yu","year":"2025","unstructured":"Yu Y, Ding Y, Wang S, et al. Gut microbiota dysbiosis and its impact on type 2 diabetes: from pathogenesis to therapeutic strategies. Metabolites. 2025;15(6):397. https:\/\/doi.org\/10.3390\/metabo15060397.","journal-title":"Metabolites"},{"key":"2026_CR47","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf340","author":"X Zhou","year":"2025","unstructured":"Zhou X, Zheng W, Kong W, et al. Glucose parameters, inflammation markers, and gut microbiota changes of gut microbiome-targeted therapies in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2025. https:\/\/doi.org\/10.1210\/clinem\/dgaf340.","journal-title":"J Clin Endocrinol Metab"},{"key":"2026_CR48","doi-asserted-by":"publisher","first-page":"107696","DOI":"10.1016\/j.micpath.2025.107696","volume":"205","author":"J Ma","year":"2025","unstructured":"Ma J, Wu D, Xu C, et al. Lactobacillus salivarius alleviated dextran sulfate sodium (DSS)-induced colitis in mice by mitigating oxidative stress and inflammatory responses through modulation of the intestinal flora. Microb Pathog. 2025;205:107696. https:\/\/doi.org\/10.1016\/j.micpath.2025.107696.","journal-title":"Microb Pathog"},{"issue":"6","key":"2026_CR49","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3748\/wjg.v29.i6.1026","volume":"29","author":"FEM Ali","year":"2023","unstructured":"Ali FEM, Ibrahim IM, Ghogar OM, et al. Therapeutic interventions target the NLRP3 inflammasome in ulcerative colitis: comprehensive study. World J Gastroenterol. 2023;29(6):1026\u201353. https:\/\/doi.org\/10.3748\/wjg.v29.i6.1026.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"2026_CR50","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1210\/clinem\/dgae783","volume":"110","author":"Y Feng","year":"2025","unstructured":"Feng Y, Shang B, Yang Y, et al. Impact of DPP-4 inhibitors on interleukin levels in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2025;110(4):1195\u2013204. https:\/\/doi.org\/10.1210\/clinem\/dgae783.","journal-title":"J Clin Endocrinol Metab"},{"key":"2026_CR51","doi-asserted-by":"publisher","first-page":"115271","DOI":"10.1016\/j.expneurol.2025.115271","volume":"390","author":"AY Sim","year":"2025","unstructured":"Sim AY, Kim JY, Lee Y-h, et al. Neuroprotective roles of SGLT2 and DPP4 inhibitors: modulating ketone metabolism and suppressing NLRP3 inflammasome in T2D induced Alzheimer\u2019s disease. Exp Neurol. 2025;390:115271.","journal-title":"Exp Neurol"},{"key":"2026_CR52","doi-asserted-by":"publisher","first-page":"107100","DOI":"10.1016\/j.ejps.2025.107100","volume":"209","author":"AS Alshahrani","year":"2025","unstructured":"Alshahrani AS, Saber S, Alruwaili OS, et al. Modulation of FOXO3a nuclear localization by linagliptin (BI-1356) reveals a new therapeutic target in chronic ulcerative colitis. Eur J Pharm Sci. 2025;209:107100. https:\/\/doi.org\/10.1016\/j.ejps.2025.107100.","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"2026_CR53","doi-asserted-by":"publisher","first-page":"e70206","DOI":"10.1002\/jbt.70206","volume":"39","author":"MO Mahmoud","year":"2025","unstructured":"Mahmoud MO, Al-Hamid HA, Hassan NF, et al. Linagliptin mitigates DMH-induced colorectal cancer in rats: crosstalk between NFAT and IL-6\/JAK2\/STAT3\/NF-\u03baB signaling hubs. J Biochem Mol Toxicol. 2025;39(3):e70206. https:\/\/doi.org\/10.3389\/fphar.2024.1456058.","journal-title":"J Biochem Mol Toxicol"},{"key":"2026_CR54","doi-asserted-by":"publisher","first-page":"1456058","DOI":"10.3389\/fphar.2024.1456058","volume":"15","author":"EA Elmorsy","year":"2024","unstructured":"Elmorsy EA, Youssef ME, Abdel-Hamed MR, et al. Activation of AMPK\/SIRT1\/FOXO3a signaling by BMS-477118 (saxagliptin) mitigates chronic colitis in rats: uncovering new anti-inflammatory and antifibrotic roles. Front Pharmacol. 2024;15:1456058. https:\/\/doi.org\/10.3389\/fphar.2024.1456058.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2026_CR55","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s11096-024-01828-5","volume":"47","author":"N Zaghloul","year":"2025","unstructured":"Zaghloul N, Awaisu A, Mahfouz A, et al. Evaluating the appropriateness and the factors associated with sodium-glucose co-transporter 2 inhibitors prescribing in a Middle Eastern country: a cross-sectional study. Int J Clin Pharm. 2025;47(2):314\u201324. https:\/\/doi.org\/10.1007\/s11096-024-01828-5.","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"2026_CR56","doi-asserted-by":"publisher","first-page":"67","DOI":"10.18553\/jmcp.2020.26.1.67","volume":"26","author":"D Gor","year":"2020","unstructured":"Gor D, Lee TA, Schumock GT, et al. Adherence and persistence with DPP-4 inhibitors versus Pioglitazone in type 2 diabetes patients with chronic kidney disease: a retrospective claims database analysis. J Manag Care Spec Pharm. 2020;26(1):67\u201375. https:\/\/doi.org\/10.18553\/jmcp.2020.26.1.67.","journal-title":"J Manag Care Spec Pharm"},{"issue":"9","key":"2026_CR57","doi-asserted-by":"publisher","first-page":"108827","DOI":"10.1016\/j.jdiacomp.2024.108827","volume":"38","author":"S Sarma","year":"2024","unstructured":"Sarma S, Hodzic-Santor B, Raissi A, et al. Association of sodium glucose co-transporter-2 inhibitors with risk of diabetic ketoacidosis among hospitalized patients: a multicentre cohort study. J Diabetes Complic. 2024;38(9):108827. https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108827.","journal-title":"J Diabetes Complic"},{"issue":"5","key":"2026_CR58","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.1007\/s11357-024-01214-z","volume":"46","author":"HSM Jayarathne","year":"2024","unstructured":"Jayarathne HSM, Sullivan R, Stilgenbauer L, et al. Hypothalamic sex-specific metabolic shift by canagliflozin during aging. Geroscience. 2024;46(5):4479\u201393. https:\/\/doi.org\/10.1007\/s11357-024-01214-z.","journal-title":"Geroscience"},{"issue":"10","key":"2026_CR59","doi-asserted-by":"publisher","first-page":"e2237606","DOI":"10.1001\/jamanetworkopen.2022.37606","volume":"5","author":"PT Htoo","year":"2022","unstructured":"Htoo PT, Tesfaye H, Schneeweiss S, et al. Comparative effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in older adults with diverse patient characteristics. JAMA Netw Open. 2022;5(10):e2237606. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.37606.","journal-title":"JAMA Netw Open"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02026-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-02026-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02026-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:07:54Z","timestamp":1763554074000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-02026-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2026"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-02026-7","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"6 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of Tri-Service General Hospital (Approval Number: E202416047, approved on December 11, 2024). Informed consent was waived due to the use of de-identified secondary data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}